CME Group Inc. · CME · FY2024 Q3 · Calendar Q4 2024

CME posts record Q3 volume as international and crypto trading accelerate

The quarter supports a constructive operating thesis: record volume, international expansion, crypto-futures adoption and client acquisition are reinforcing growth. That support is balanced by competition, regulatory uncertainty, possible RPC pressure and higher licensing costs.

Reported Before market openNASDAQFinancial Services $105.55B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.68 Consensus $2.66
EPS surprise +0.8% Reported versus consensus
Reported revenue $1.58B Consensus $1.59B
Revenue surprise -0.3% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +0.4% Event window
SPY move -0.9% Same window
Abnormal move +1.3% Stock minus SPY
Volume 1.2× Versus trailing sessions
Subsequent drift +0.4% Up to 20 sessions
CMESPY benchmark

Ask FN2 about CME FY2024 Q3

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the latest analysis shifts from a broad record-results and cloud-investment story to stronger evidence of international, crypto and client-acquisition momentum. It also identifies a stable capex outlook and continued attention to FMX competition, licensing costs and overseas Treasury-clearing regulation.

Guidance delta

Management maintained guidance; the analysis also notes a lower effective tax-rate range of 22.5%–23% for the year.

Key takeaways

  • Record average daily volume and revenue reflected broad-based operating leverage.
  • International growth was prominent, with EMEA and APAC average daily volume up 30% and 28%, respectively.
  • Crypto futures and micro contracts expanded rapidly, while margin-saving programs supported client value.
  • New client acquisition increased across retail and institutional segments.

Management priorities

  • Continue product innovation in crypto and energy offerings.
  • Expand margin-efficiency programs and international client acquisition.
  • Invest in cloud migration and technology upgrades.
  • Maintain openness to strategic M&A while monitoring capital returns.

Follow CME with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
CME REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $1B Q4 '23 actual $1B, beat Q1 '24 estimate $1B Q1 '24 actual $1B, beat Q2 '24 estimate $2B Q2 '24 actual $2B, match Q3 '24 estimate $2B Q3 '24 actual $2B, miss Q2 '25 estimate $2B Q2 '25 actual $2B, beat Q3 '25 estimate $2B Q3 '25 actual $2B, beat Q4 '25 estimate $2B Q4 '25 actual $2B, match Q1 '26 estimate $2B Q1 '26 actual $2B, beat Q2 '26 estimate $2B Q2 '26 actual $2B, beat Q3 '26 estimate $2B Q4 '26 estimate $2B Q1 '27 estimate $2B Q2 '27 estimate $2B
Show less

Analyst Consensus ?

ConsensusHold36 ratings
Bullish1438.9%
Neutral1747.2%
Bearish513.9%

Analyst 52W Price Targets

$293.53Current
$151Low
$255.77Average
$337High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 20, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 14, 2026
Morgan Stanley Overweight OverweightMaintainOct 9, 2026
Barclays Equal Weight Equal WeightMaintainOct 7, 2026
UBS Neutral NeutralMaintainOct 5, 2026
TD Cowen Buy BuyMaintainOct 5, 2026
Show 31 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $293.53. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Wells FargoDaniel Welden$315$278.03 +7.3%Oct 14, 2026
Morgan StanleyAnalyst unavailable$337$276.44 +14.8%Oct 9, 2026
BarclaysAnalyst unavailable$281$270.18 -4.3%Oct 7, 2026
UBSAlex Kramm$270$263.14 -8.0%Oct 5, 2026
Wells FargoDaniel Welden$301$265.1 +2.5%Oct 1, 2026
See 67 more

Track every rating change on CME the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

CME Group Inc., through its various subsidiaries, manages international marketplaces for the exchange of futures and options on futures contracts worldwide. Its extensive array of product offerings includes futures and options linked to a broad spectrum of underlying assets, such as interest rates, equity indices, foreign exchange, agricultural commodities, energy, and metals, alongside fixed-income products.…

Historical context

All CME earnings

Financial Services peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the CME recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
  3. Polygon adjusted daily market bars · 2026-10-20T04:40:42.414030+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-20T04:40:42.411253+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-20. For educational purposes only; not investment advice.